The prospective clinical use of multipotent mesenchymal stromal stem cells (MSC) holds enormous promise for the treatment of a large number of degenerative and age-related diseases. However, the challenges and risks for cell-based therapies are multifaceted. The risks for patients receiving stem cells, which have been expanded in vitro in the presence of xenogenic compounds, can hardly be anticipated and methods for the culture and manipulation of "safe" MSC ex vivo are being investigated.
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Abstract:
The prospective clinical use of multipotent mesenchymal stromal stem cells (MSC) holds enormous promise for the treatment of a large number of degenerative and age-related diseases. However, the challenges and risks for cell-based therapies are multifaceted. The risks for patients receiving stem cells, which have been expanded in vitro in the presence of xenogenic compounds, can hardly be anticipated and methods for the culture and manipulation of "safe" MSC ex vivo are being investigated.
During in vitro expansion, stem cells experience a long replicative history and are thus subject to damage from intracellular and extracellular influences. While murine MSC are prone to cellular transformation in culture, human MSC do not transform. One reason for this striking difference is that during long-term culture, human MSC finally become replicatively senescent. In consequence, this greatly restricts their proliferation and differentiation efficiency. It however also limits the yield of sufficient numbers of cells needed for therapy.
Another issue is to eliminate contamination of expanding cells with serumbound pathogenic agents in order to reduce the risks for infection. A recent technical advancement, which applies human serum platelet lysates as an alternative source for growth factors and essential supplements, allows the unimpaired proliferation of MSC in the absence of animal sera. Here, we present an update regarding cellular senescence of MSC and recent insights concerning potential risks associated with their clinical use.
3 Background Stem cells are vitally involved in tissue regeneration and homeostasis in later life. Mesenchymal (skeletal) stem cells (MSC) (also known as multipotent stromal progenitor cells, or marrow stromal cells) are but one particular type of the so-called tissue-specific (or adult) stem cells. This term refers to stem cells derived from postnatal tissues, and this type of stem cell is generally believed to be multi-or oligopotent. MSC can differentiate into mesoderm-type cells, such as osteoblasts, chondrocytes, and adipocytes.
The clinical use of MSC is an emerging field, and part of the so-called regenerative medicine. MSC are envisaged to be employed for the treatment of a number of diseases including non-healing bone defects and fractures, inflammatory arthritis, and repair of suspensory ligament tears . Furthermore, application of MSC is thought to enhance hematopoietic stem cell engraftment in the course of bone marrow transplantation , to correct inherited disorders of bone and cartilage (Bolland et al., 2007) , to ameliorate tissue damage after myocardial infarction (Abdel-Latif et al., 2007) , and to treat graft-versus-host disease (Ringden et al., 2006) . Also, attempts are being undertaken to employ MSC as a vehicle for gene therapy, e.g. in osteogenesis imperfecta (Chamberlain et al., 2008; Pochampally et al., 2005) . For other clinical indications presently being tested, please see: www.ClinicalTrial.gov.
Since elderly patients are the main target population for this type of therapy, one important issue is to investigate the changes that occur in MSC with age.
Studying this aspect of stem cell biology also offers the particular opportunity to define fundamental principles of how cells and tissues change during adulthood.
Fundamental in this context is also research on the stem cells' niches, i.e. their microenvironment and the respective molecular composition, as well as the cellular response upon systemically acting endocrinological and immunological factors.
Aging, in vitro senescence and MSC 4
The relationship between aging and stem cells is important for a number of reasons. The effect of in vitro senescence on stem cell properties is an important topic for understanding the aging process per se, which is the basis of identifying those molecular targets that may delay or "rescue" the deleterious effects of senescence on stem cells. One option for cell-based therapies is autologous stem cell transplantation. In this respect, it is of prime interest to assess the impact of donor age on MSC biology. Often, there is a need for extensive cell amplification in vitro in order to obtain high enough numbers of cells to ensure the success of a cell-based therapy. However, in vitro expansion ultimately leads to cellular senescence and poses a risk of accumulating genetic and epigenetic changes to the cells, which in turn may also lead to cellular transformation and cancer ( Figure 1 ). For this reason, it is a topic of major interest whether stem cells are bound to transform spontaneously in vitro.
MSC: biology and characteristics
Currently, it seems that there is no "universal" source for stem cells suitable for all conceivable clinical applications. It greatly believed that besides embryonic stem cells also different types of specialized, tissue-specific stem cells from adult donors will be employed for different therapies.
The conceptualization of the MSC as a prominent example of an adult stem cell was put forward by Owen and Friedenstein largely based on pioneering experimental studies performed in the 60s and 70s in Russia (Friedenstein et al., 1966; Luria et al., 1971; Owen and Friedenstein, 1988) . The notion was popularized by Arnold Caplan in the late 80's and throughout the 90's (Caplan, 1991) . Over the past decade, MSC have been the focus of a large number of experimental studies (overview of results see Figure 2 ). By now it is generally accepted that MSC can differentiate into a number of differently committed progenitor cell types, e.g. into osteoblasts, chondrocytes, and adipocytes as well as hematopoietic supportive stromal cells (Barry et al., 2001; Bruder et al., 1998; Cancedda et al., 2003; Caplan, 2007; Kassem et al., 1991; Le Blanc and Pittenger, 2005; Prockop, 1997) . There have also been reports suggesting that these cells differentiate to cardiomyocytes (Wakitani et al., 1995) , hepatocytes (Lee et al., 2004) or neuronal cells (Woodbury et al., 2000) , but these incipient studies need further confirmation. Currently, bone marrow, subcutaneous 5 adipose tissue and umbilical cord blood are among the main sources for isolating MSC. Typically MSC are obtained from these tissue preparations by plastic adherence. Consequently, the resulting cell cultures contain not only MSC, but also lineage-committed progenitors (Kuznetsov et al., 1997; Post et al., 2008) .
Due to the ease of obtaining these cells, MSC can be transplanted either directly as undifferentiated cells, allowing differentiation processes to take place through induction of locally-acting tissue factors, or alternatively, MSC can be expanded in culture first, before differentiating them appropriately in vitro, to obtain large numbers of cells with a distinctly defined phenotype.
MSC in vitro senescence
Both intrinsic and extrinsic aging processes affect stem cell properties Rando, 2006) . One possible intrinsic cellular aging mechanism is replicative or cellular senescence. In 1961, Hayflick and Moorhead discovered that in vitro, human skin fibroblasts undergo only a limited number of population doublings (termed Hayflick limit), and that this number decreased with increasing donor age (Hayflick and Moorhead, 1961) . Similar to other human diploid cells, MSC exhibit replicative senescence in vitro, as demonstrated by a number of investigators (Fehrer et al., 2007; Kern et al., 2006; Stenderup et al., 2003; Stenderup et al., 2004; Stolzing et al., 2008) . The in vitro senescent phenotype includes the following characteristic features: (i) irreversible arrest of cell division (in contrast to quiescence, where this lock is reversible), (ii) resistance to apoptotic death, and (iii) the excretion of molecules normally secreted during wound repair and infection, such as inflammatory cytokines, proteases and growth factors, the latter having detrimental consequences for the surrounding tissue (Campisi, 2001) . Some, but not all of these characteristics have also been described for MSC cultures (Fehrer et al., 2007; Kern et al., 2006; Stenderup et al., 2003; Stenderup et al., 2004; Stolzing et al., 2008) The presence of cells in vivo, which closely resemble the phenotype of senescent cells replicatively aged in culture, has been observed in human skin 6 (Dimri et al., 1995; Ressler et al., 2006) as well as in the vascular system (Vasile et al., 2001) . It is thus conceivable that also stem cells reach an equivalent state of senescence in vivo, but the proof of this hypothesis is still missing.
In vitro senescence and epigenetics:
Gene expression is controlled by transcription factors. Their respective activities are influenced by the chromatin structure. This in turn is modulated by chromatin remodeling factors, which modify the balance between euchromatin and heterochromatin. These particular factors are also known to be involved in determining self-renewal, proliferation and differentiation potential of stem cells (Boquest et al., 2006; Squillaro et al., 2008) . Chromatin remodelers such as the ATP-dependent remodeling complexes which contain Brg1 are required for cell cycle control, apoptosis and cell differentiation. Moreover, they negatively affect stem cell self-renewal properties, because they appear to be involved in the induction of senescence and apoptosis (Napolitano et al., 2007) . Other factors such as the polycomb group protein Bmi1, prevent senescence and thus maintain stem cell self-renewal at an uncommitted state (Park et al., 2004) . In particular, BMI1 represses the transcription of the cell cycle regulator p16 INK4A (Jacobs et al., 1999) . In MSC cultivated in vitro, p16 INK4A function is transcriptionally inactivated by DNA methylation in the core promoter region (Shibata et al., 2007) . Down-regulation of p16 INK4A expression results in the escape from senescence and the restoration of the cell's proliferating activity.
These few examples clearly highlight the need for the careful balancing of sitespecific chromatin remodeling to distinctly determine stem cell properties, while at the same time reducing enhanced cellular aging.
MSC, telomere and telomerase
Telomeres are repetitive DNA sequences at the physical ends of chromosomes.
They are responsible for the maintenance of chromosome stability, and therefore, dysfunctional telomeres affect genome stability, and the cell's proliferative capacity. The most terminal, single-stranded region of telomeres loop back and pair with an internal double-stranded location forming a stable loop structure -the telomeric cap (Griffith et al., 1999) . Cells with telomeres in their capped state exhibit enhanced proliferative capacity, whereas the uncapped form coincides with cell cycle arrest (Blasco, 2007b) . In the absence of the enzyme telomerase, in many somatic cells including MSC, the telomeres gradually become shorter as the cell division proceeds The net impact is the successive telomere shortening during DNA replication with every cell division (Garcia et al., 2007; Harley, 2008; Shay and Wright, 2007) . A direct consequence is the inactivation of genes closest to the telomere sequences, which is either directly, or indirectly by a positional effect, involving the formation of heterochromatin (Blasco, 2007a) . Constitutive expression of the catalytic subunit of the telomerase gene, hTERT prevents replicative senescence and maintains "stemness" characteristics of MSC (Simonsen et al., 2002) . Also regulated telomere maintenance by ectopic expression of hTERT sustains stem cell properties in MSC . It could be shown recently that treatment of MSC with trichostatin A resulted in transient expression of hTERT (Serakinci et al., 2006) . In line with this, MSC that had been stalled in the cell cycle by serum deprivation, transiently expressed telomerase activity during the S phase (Zhao et al., 2008) . Whether this periodic upregulation of telomerase activity is high enough to retain telomeric capping function, and thus inducing relevant biological effects, remains to be determined. Clearly, more research needs to be performed for the detailed understanding of how to counteract telomere shortening in MSC when expanding them in vitro.
MSC and cell-based therapies: concerns and potential hazards
MSC and serum-containing culture media
Most research laboratories culture MSC in media containing 10-20% fetal calf serum. The use of animal, in particular bovine products involves the risk of prion transmission, and/or yet unidentified zoonoses as well as the activation of the host immune system by biomolecules, which are foreign to the human species.
Alternatives to that have been introduced lately: (i) freshly frozen plasma and platelets (Muller et al., 2006) , or (ii) platelet lysate (Doucet et al., 2005) . Careful side-by-side comparisons using media containing either calf serum or human platelet lysate (hPL) showed that MSC exhibit enhanced proliferation rates in hPL without changing morphology, immunophenotype or differentiation capacity.
No apparent genetic abnormalities were detectable upon this treatment 8 Lange et al., 2007) . The cells also retained their immune-modulatory potential. More than that, they showed a more efficient suppression of allo-antigen-induced lymphocyte proliferation (Bernardo et al., 2007a) . Furthermore, they were void of tumorgenicity when implanted into nude mice . Another alternative to fetal calf serum is autologous patient serum. However, it appears to be less favorable, since serum derived from aged individuals interferes with MSC proliferation and/or differentiation capacity (Abdallah et al., 2006; Mannello and Tonti, 2007) .
MSC and transformation risk
There are concerns that transplanted, culture expanded MSC may undergo spontaneous transformation. It is also thought that similar problems may arise, when MSC derived from aged donors are employed in cell therapy (Li et al., 2007) . This conclusion however is based on extrapolations from studies performed on murine MSC. During long-term culture, murine MSC accumulate chromosomal aberrations and exhibit a malignant transformation phenotype (Zhou et al., 2006) . The resulting MSC, when implanted into immunecompromised mice using hydroxyapatite/tricalcium phosphate as a carrier, as well as when injected into the tail vein led to sarcoma formation (Miura et al., 2006) . Murine MSC also rapidly acquire chromosomal abnormalities in culture, and after infusion, these cells invaded lung parenchyma and formed tumor nodules with the characteristics of differentiated osteosarcomas (Aguilar et al., 2007) . Compared to murine MSC, human MSC in long-term culture greatly differ in their behavior. Two recent reports demonstrated that human bone marrowderived MSC are not bound to undergo transformation when propagated in long-term culture (Miura et al., 2006; Zhou et al., 2006) , and under the same culture conditions, human MSC do not exhibit obvious chromosomal abnormalities at late passages (Bernardo et al., 2007b ). Bernardo and colleagues performed extensive genetic characterizations using comparative genomic hybridization, karyotyping and subtelomeric fluorescent in situ hybridization analysis, telomerase activity as well as assessing the alternative lengthening of telomere at different stages of long-term culture. The authors found no evidence for transformation of human MSC during long term culture.
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This issue is however still under debate, because two studies in the literature reported that MSC in vitro may exhibit spontaneous transformation. In one study, Rubino et al refer to adipose-tissue-derived MSC from young children do transform spontaneously in long-term culture . The cells employed in these cultures were however not obtained from healthy individuals but isolated from subcutaneous fat during operation of complicated appendicitis and it is thus likely that they are not comparable to normal MSC Kassem et al., 2005) . The second study broaches the issue of spontaneous transformation in the unphysiological case of immortalizing human MSC with hTERT, thereby gaining high levels of telomerase activity Serakinci et al., 2004) . Such MSC showed various genetic and epigenetic changes in spite of maintaining a normal karyotype Serakinci et al., 2004) . Taken together, there is to date good reason to believe that human bone marrow MSC that have been derived from healthy individuals in a standardized manner, do not readily transform in culture. This is in stark contrast to their instable murine counterpart and thus poses the question whether murine MSC are a suitable model system at any instance to understand their human relatives.
Another concern is whether administered MSC promote the growth of a latent tumor. MSC can be recruited to the stroma of developing tumors when systemically infused in animal models for glioma, colon carcinoma, ovarian carcinoma, Karposi's sarcoma and melanoma (Lazennec and Jorgensen, 2008) .
There is also evidence that MSC, when injected subcutaneously together with tumor cells, can increase tumor growth by increasing the rates of tumor necrosis and angiogenesis (Zhu et al., 2006) . In a breast cancer xenograft model, though having no effect on tumor growth per se, MSC greatly increased the metastasis rate through secretion of CCL5 (also called RANTES) (Karnoub et al., 2007) . It has also been shown that highly malignant bone sarcomas contain selfrenewing stem cells, which express stem cell markers such as Oct3/4 and Nanog, in parallel with the surface markers Stro-1, CD105 and CD44, a phenotype similar to MSC (Gibbs et al., 2005) .
Transplanted bone marrow contains MSC, and hematologist have used these cells in clinical therapies for decades without recognising adverse effects comparable to the aforementioned scenarios. This let us to conclude that the relevance of these experimental studies for MSC-based cell therapies is perhaps limited. However, it should be also noted here that further investigations of how MSC and their stromal derivatives compromise cancer cells is a mandatory future research field in order to understand, and consequently influence tumor progression.
In conclusion, there is increasing evidence that with respect to the risk of MSC transformation and subsequent tumor formation initiated by MSC, human MSC appear to be safe. We however feel impelled to strongly recommend at this point careful quality control procedures for all cell preparations. These should be implemented for all kinds of cell-based therapies. Suffice it to say that before administering MSC to patients the cell preparations have to undergo carefull phenotypic, functional and genetic characterizations.
Concluding remarks:
The record of safety for MSC in general is excellent and we anticipate that after successful conclusion of ongoing preclinical and clinical tests, MSC will be gradually introduced into clinical practice for a number of disease conditions in the coming years. Careful pre-administration safety monitoring as well as close monitoring of the patients are important pre-requisites for the success of this novel form of therapy. Regulatory bodies such as the US Food and Drug administration (Halme and Kessler, 2006) They are also involved in regeneration and repair during adulthood. In addition, MSC nurture stromal compartments with cells, which themselves are important regulators of stem cell renewal, in particular in the case of hematopoietic stem and precursor cells. Moreover, MSC exert immune modulatory properties.
These processes are intricately dependent on the supervision of the niche, which is but a part of the organ that constantly undergoes changes due to metabolic activity, pathologic insults and biological aging. 
